The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is ...

If you watched Kim Kardashian's latest health update and felt a jolt at the phrase "holes on the brain," you were not alone. It is a term that sounds catastrophic. Yet on the type of scan she had, a ...

Silent cells deep in your spinal cord may hold a surprising key to healing after devastating injuries and brain disease. A ...

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.

The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but ...

Epidemiological studies are essential in understanding the causes, risk factors of diseases, and disease patterns for ...

DENVER, CO / / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous ...

A new study from the University of Haifa suggests that disorders as different as Alzheimer’s, schizophrenia, and autism may ...

Some recent studies have suggested that there is a link between severe gum disease or periodontitis, and some disorders that ...

Neurological disorders represent a mounting public health crisis in China, exacerbated by rapid population ageing. Cerebrovascular diseases and ...

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology ...

The process of “epigenetic memory” in nerve cells plays a key role in learning ability, memory function, and healthy brain ...